April 06, 2021
For patients sent for an unplanned PCI, a strategy of maintaining oral anticoagulation is not associated with a higher risk of ischemic complications or bleeding when compared with a strategy of interrupting the direct oral anticoagulant (DOAC) or vitamin K antagonist (VKA) a day or two before the procedure, a new observational analysis confirms.
Published in the April 12, 2021, issue of
JACC: Cardiovascular Interventions, the study, drawing on the large SWEDEHEART registry, supports the current recommendations from the European Society of Cardiology (ESC) for uninterrupted oral anticoagulation (U-OAC) in patients with atrial fibrillation, venous thromboembolism, or a mechanical heart valve undergoing unplanned, nonemergent PCI, investigators say.
Antithrombotics for Elderly CAD Patients: One Size Doesn t Fit All tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.
February 09, 2021
Two additional randomized trials along with other analyses published since 2018 have helped to firm up formal guidance around antithrombotic therapy in patients with atrial fibrillation (AF) who are undergoing PCI.
Published yesterday, the updated North American consensus statement continues to recommend triple therapy with a direct oral anticoagulant (DOAC), a P2Y12 inhibitor, and aspirin during the peri-PCI period, after which the aspirin should be discontinued, according to experts from the United States and Canada.
That’s similar to what the group recommended in the last update published in 2018, but the publication of the AUGUSTUS and ENTRUST-AF PCI trials in the past few years “provides a lot of reassurance on the importance of an early discontinuation of aspirin in these patients,” lead author Dominick Angiolillo, MD, PhD (University of Florida College of Medicine – Jacksonville), told TCTMD.